Syndax Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
03/03/2025 15:25
Syndax Pharmaceuticals Inc SNDX.OQ reported a quarterly adjusted loss of $1.10 per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $-1.00. The mean expectation of thirteen analysts for the quarter was for a loss of 23 cents per share. Wall Street expected results to range from $-1.27 to $3.49 per share. Revenue was $7.68 million; analysts expected $85.91 million. Syndax Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.10. The company reported a quarterly loss of $94.17 million. Syndax Pharmaceuticals Inc shares had risen by 18.3% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 1,560.5% in the last three months. In the last 30 days, two analysts negatively revised earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $35.50 This summary was machine generated from LSEG data March 3 at 03:24 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.23 | -1.10 | Missed |
| Sep. 30 2024 | -1.11 | -0.98 | Beat |
| Jun. 30 2024 | -0.91 | -0.80 | Beat |
| Mar. 31 2024 | -0.98 | -0.85 | Beat |
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million